« Back to Record
Citation APA

Schram, A. A., Colombo, N., Arrowsmith, E., Narayan, V., Yonemori, K., Scambia, G., Zelnak, A. A., Bauer, T. T., Jin, N., Ulahannan, S. S., Colleoni, M. A., Aftimos, P., Donoghue, M. M., Rosen, E., Rudneva, V. V., Telli, M. M., Domchek, S. S., Galsky, M. D., Hoyle, M., Chappey, C., Stewart, R., Blake-Haskins, J. J., & Yap, T. A. (2023). Avelumab Plus Talazoparib in Patients with BRCA1/2 - Or ATM -Altered Advanced Solid Tumors: Results from JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial. JAMA oncology, 9(7), 1009. doi:10.1001/jamaoncol.2022.5218


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/374663

Schram, A. A., Colombo, N., Arrowsmith, E., Narayan, V., Yonemori, K., Scambia, G., Zelnak, A. A., Bauer, T. T., Jin, N., Ulahannan, S. S., Colleoni, M. A., Aftimos, P., Donoghue, M. M., Rosen, E., Rudneva, V. V., Telli, M. M., Domchek, S. S., Galsky, M. D., Hoyle, M., Chappey, C., Stewart, R., Blake-Haskins, J. J., & Yap, T. A. (2023). Avelumab Plus Talazoparib in Patients with BRCA1/2 - Or ATM -Altered Advanced Solid Tumors: Results from JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial. JAMA oncology, 9(7), 1009. doi:10.1001/jamaoncol.2022.5218